Zobrazeno 1 - 10
of 280
pro vyhledávání: '"MUTANT KRAS"'
Autor:
Eszter Molnár, Marcell Baranyi, Krisztina Szigeti, Luca Hegedűs, Fanni Bordás, Zsófia Gábriel, Gréta Petényi, József Tóvári, Balázs Hegedűs, József Tímár
Publikováno v:
Pathology and Oncology Research, Vol 30 (2024)
Pancreatic adenocarcinoma is one of the deadliest forms of cancer with no effective therapeutic options. A KRAS mutation can be found in up to 90% of all pancreatic tumors, making it a promising therapeutic target. The introduction of new KRAS inhibi
Externí odkaz:
https://doaj.org/article/218556c3ae364339970c587752baa280
Autor:
Yoon Sun Park, Joseph kim, Yea Seong Ryu, Jai-Hee moon, Yu Jin shin, Jeong Hee kim, Seung-Woo hong, Soo-A jung, Seul lee, Seung-Mi kim, Dae Hee lee, Do Yeon kim, Hyeseon yun, Ji-Eun you, Dong Il yoon, Chul Hee kim, Dong-In koh, Dong-Hoon jin
Publikováno v:
Cancer Biology & Therapy, Vol 24, Iss 1 (2023)
Significant improvement in targeted therapy for colorectal cancer (CRC) has occurred over the past few decades since the approval of the EGFR inhibitor cetuximab. However, cetuximab is used only for patients possessing the wild-type oncogene KRAS, NR
Externí odkaz:
https://doaj.org/article/1768709d29094b5387a1c7c373462d07
Publikováno v:
Journal of Translational Medicine, Vol 21, Iss 1, Pp 1-16 (2023)
Abstract Background Histone deacetylases (HDAC) contribute to oncogenic program, pointing to their inhibitors as a potential strategy against cancers. We, thus, studied the mechanism of HDAC inhibitor ITF2357 in resistance of mutant (mut)-KRAS non-sm
Externí odkaz:
https://doaj.org/article/28ae769541ad43188dac07f88724d3bf
Autor:
Jacob E. Larson, P. Brian Hardy, Noah K. Schomburg, Xiaodong Wang, Dmitri Kireev, Kent L. Rossman, Kenneth H. Pearce
Publikováno v:
SLAS Discovery, Vol 28, Iss 1, Pp 39-47 (2023)
Mutations in the small GTPase protein KRAS are one of the leading drivers of cancers including lung, pancreatic, and colorectal, as well as a group of developmental disorders termed “Rasopathies”. Recent breakthroughs in the development of mutant
Externí odkaz:
https://doaj.org/article/d51a173c0d3d402c8c67f70bb132faf6
Autor:
Hang Ruan, Brian J. Leibowitz, Yingpeng Peng, Lin Shen, Lujia Chen, Charlie Kuang, Robert E. Schoen, Xinghua Lu, Lin Zhang, Jian Yu
Publikováno v:
Molecular Biomedicine, Vol 3, Iss 1, Pp 1-16 (2022)
Abstract Mutant KRAS is a key driver in colorectal cancer (CRC) and promotes Myc translation and Myc-dependent stress adaptation and proliferation. Here, we report that the combination of two FDA-approved drugs Bortezomib and Everolimus (RAD001) (BR)
Externí odkaz:
https://doaj.org/article/897eff7e4d3547fe9e1e5347bbb62633
Autor:
Huashan Liu, Zhenxing Liang, Sijing Cheng, Liang Huang, Wenxin Li, Chi Zhou, Xiaobin Zheng, Shujuan Li, Ziwei Zeng, Liang Kang
Publikováno v:
Advanced Science, Vol 10, Iss 6, Pp n/a-n/a (2023)
Abstract The roles of oncogenic KRAS in tumor immune evasion remain poorly understood. Here, mutant KRAS is identified as a key driver of tumor immune evasion in colorectal cancer (CRC). In human CRC specimens, a significant reduction in cytotoxic CD
Externí odkaz:
https://doaj.org/article/3a6a099b6f4244b6a491a210edd9fb72
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Xiang Ling, Wenjie Wu, Ieman A. M. Aljahdali, Jianqun Liao, Sreevidya Santha, Christos Fountzilas, Patrick M. Boland, Fengzhi Li
Publikováno v:
Clinical and Translational Medicine, Vol 12, Iss 5, Pp n/a-n/a (2022)
ABSTRACT Background Pancreatic ductal adenocarcinoma (PDAC), a difficult‐to‐treat cancer, is expected to become the second‐largest cause of cancer‐related deaths by 2030, while colorectal cancer (CRC) is the third most common cancer and the t
Externí odkaz:
https://doaj.org/article/ff7f5691688d42929e672fe9ee33b6d4
Publikováno v:
Cells, Vol 11, Iss 16, p 2490 (2022)
KRAS mutations have been shown to extend their oncogenic effects beyond the cancer cell, influencing the tumor microenvironment. Herein, we studied the impact of mutant KRAS on the modulation of the pro-tumorigenic properties of cancer-associated fib
Externí odkaz:
https://doaj.org/article/ec2c3338ba0a4db2a804ca312c75175f
Publikováno v:
Cells, Vol 11, Iss 13, p 1988 (2022)
Understanding how mutant KRAS signaling is modulated by exogenous stimuli is of utmost importance to elucidate resistance mechanisms underlying pathway inhibition failure, and to uncover novel therapeutic targets for mutant KRAS patients. Hence, aimi
Externí odkaz:
https://doaj.org/article/ad7176ed763241caa3b73e09042363d7